Over 1000 patients have benefited from STENTYS Self-Apposing technology

PRINCETON, N.J., and PARIS, Sept. 15, 2011 — STENTYS S.A. (FR0010949404, STNT.PA), a medical technology company that is commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that its Self-Apposing Stent has been implanted into more than 1000 patients internationally.

“There is a clear adoption pattern underway of the STENTYS Self-Apposing Stent to routinely treat AMI patients in the hospitals where we have started marketing our product,” said Gonzague Issenmann, CEO and co-founder of STENTYS. “The ability to solve the stent sizing dilemma that cardiologists are confronted with in many cases with conventional stents, as well as the elimination of its dreadful consequence, malapposition, are recognized as a real breakthrough by our customers and make the STENTYS stent an indispensable tool for every cath lab”.

The self-apposing feature of the STENTYS stent ensures optimal apposition during thrombus and vessel spasm relief in the critical initial hours and days after an AMI procedure, thereby avoiding malapposition, a cause of thrombotic events and repeat myocardial infarction, and a significant concern to cardiologists. The APPOSITION II randomized trial compared the STENTYS Self-Apposing Stent with a conventional, market-leading stent in patients suffering a heart attack. It showed that, three days after an AMI, 28% of patients treated with conventional stents displayed severe malapposition, meaning that the stent was not completely in contact with the artery wall, whereas none of the patients treated with STENTYS had any malapposition.

Acute Myocardial Infarction (AMI) affects 100,000 people each year in France and an additional 900,000 people in the United States and represents an annual worldwide market of approximately $2 billion.

- Next press release

Revenues for the 3rd quarter of 2011 will be published on 9 November 2011, after market.

About STENTYS:
Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Ségui, M.D., Ph.D., and Gonzague Issenmann, STENTYS received CE marking for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. STENTYS has marketing activities in several European countries.


This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

STENTYS
Stanislas Plot
CFO
Tel. : +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Investor Relations
Axelle Vuillermet / Pierre Laurent
Tel. : +33 (0)1 44 71 94 93
stentys@newcap.fr

STENTYS is listed on NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT